Goldman Sachs’s CalciMedica CALC Stock Holding History

Goldman Sachs’s Portfolio CALC Stock Details CALC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-2,194	Closed	-$170K	–	6214
2021 Q1	$170K	Buy	+2,194	New	+$657K	﹤0.01%	5696
2020 Q4	–	Sell	-4,014	Closed	-$714K	–	5495
2020 Q3	$714K	Buy	+4,014	New	+$837K	﹤0.01%	4291

Other funds holding CALC

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

Goldman Sachs's CALC Position: Q2 2021 in Review

Goldman Sachs sold out of CalciMedica (CALC) in Q2 2021, closing a stake of 2,194 shares — an estimated $170K sold.

Goldman Sachs first reported a position in CALC in Q3 2020 and held it in 2 quarters. The position peaked at $714K in Q3 2020. 41 funds tracked by Wall St. Rank hold CALC as of Q2 2021.

Goldman Sachs reported no remaining CalciMedica position as of Q2 2021 after selling out during the quarter.
Goldman Sachs sold 2,194 CalciMedica shares in Q2 2021, an estimated $170K.
Goldman Sachs first reported a position in CalciMedica in Q3 2020 and held it in 2 quarters.
Goldman Sachs's CalciMedica position peaked at $714K in Q3 2020.
41 funds tracked by Wall St. Rank held CalciMedica as of Q2 2021.

Based on Goldman Sachs's 13F filing for Q2 2021, filed 13 Aug 2021.